Zenas Biopharma’s (ZBIO) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Zenas Biopharma (NASDAQ:ZBIO – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $30.00 target price on the stock. Several other analysts also recently weighed in on the company. Wedbush restated an “outperform” rating and issued a […]
